



Index to Volume 20

Subject Index

- A
A375-6 cell growth inhibition, 121
AAL, 99, 267
AAL chromatography, 477
2-AB labeled oligosaccharides
 charge analysis of, 476
 preparation, 475
 structural analysis of, 476
2-AB labeled sugar chains, glycosidase digestion of, 475
Abnormal biantennary structure
 in carcinoembryonic antigen, 473
 in γ -glutamyltranspeptidases, 474
Abnormal biantennary sugar chain
 formation mechanism, 479
 in hCG cell lines, 479
Absolute synthesis rate (ASR), 103
Acceptor substrate preparation, 400
Acetyltransferase activity, 552, 556
Achatinin-H
 binding, 532, 533, 535
 recognizing glycotope, 534
 α 1-acid glycoprotein. *See* AGP
Acid hydrolysis, 92
Acidic sphingomyelinase. *See* aSMase
Actin in HIV entry, 218
Activating transcription factors. *See* ATF
Active staining of
 immunoglobulin-positive cells, 375
 Mac-1, 375
 neutral sialidase, 375
 sialidase, 375
 thymus sialidase, 375
 X-NANA, 375
Activity assay for Man-P-Dol, 181
Acute Lymphoblastic Leukemia (ALL), 537
Acute-phase glycoprotein, human, 103
Acute-phase proteins, 104
Affinity chromatography column, 110
Agglutination assays
 for ASAL characterization, 526
 for CEA characterization, 526
 for DEA characterization, 526
AGP
 anti-inflammatory properties of, 104
 concentration determination, 101
 isolation, total, 100
AGP-glycoforms, 99, 102
A-kinase anchoring proteins (AKAP), 54
Alcohol-induced liver disease (ALD), 583
Aleuria aurantia lectin. *See* AAL
Alkaline hydrolysis, ganglioside
 deacetyl-lysoGD1b preparation, 14
 deacetyl-lysoGM1 preparation, 14
 deacetyl-lysoGM3 preparation, 14
Allium sativum leaf lectin. *See* ASAL
Alpha-factor
 prepro sequence, 389, 390
 signal sequence, 388
Alpha-galactosyl termini, 372
Alpha-galactosyl trisaccharide epitope, 107
Alternative splicing of ST3GalIII gene, 493, 494
Aluria aurantia lectin, 474
Alzheimer's disease, 59
Amines formation, 111
Amino acid sequence, 259, 270, 493, 546
2-aminobenzamide (2-AB), 473
2-(4-aminophenyl) ethylamine conjugate of
 hepta- β -glucoside. *See* HG-APEA
3-aminopropyltriethoxysilane (APES), 367
Amyloid precursor protein. *See* APP
Aneurinibacillus thermoaerophilus, 436
Angioblasts, 179
Angiogenesis, 179, 185
Angiogenesis stages
 cell membrane permeability, 180
 extracellular matrix production, 180
 progression, 180
Anguilla anguilla agglutinin (AAA) structure,
 545, 546, 547
Anhydrous triethylamine, 13
Anion-exchange chromatography, 119, 122
Anionogenic group, 200
Anopheles gambiae protein, 545
Antiapoptotic genes, 582
Antibodies staining thymus
 anti-epithelial cells, 381
 anti-I-Ak, 381
 anti-Mac-1, 381
 anti-Mac-2, 381
Antibodies to mucins, specificity of, 88
Antibody binding with CRP, 538
Antibody-alkaline phosphatase activity, 321
Anti-cancer agents
 betulinic acid, 563
 cis-platin, 563
 D-PDMP, 563
 GD3, 563
 L-PPMP, 563
 melphalan, 563
 tamoxifen, 563
Anti-carbohydrate IgG antibodies, human, 83
Anti-epithelial cells for staining, 381
Anti- α Gal antibody
 binding, 108, 116
 human, 107, 108
 in serum, 116
Antigen biosynthesis, 154
Anti-human N-cadherin, 483
Anti-mouse Ig system, 382
Antioxidant status, 137
Anti-SiaTn antibodies, 84, 87
Anti-TF antibodies
 isolated, 85
 purification, 84
Anti-Tn antibodies
 isolated, 86
 purification, 84
Antitumor immune response, 582, 583
Aortic smooth muscle cells. *See* A-SMC
AOSM, 83, 88
Aphids, 525, 526
Aphis craccivora midgut, 526
Apical membrane, 214
Apoptosis
 concept, 39, 71, 227
 of carcinoma cells, 157, 164, 563
 of T lymphocytes, 66
Apoptosis in breast cancer cells with
 disialosyl gangliosides, 319
 GD1b, 320
 GD3, 320
Apoptosis promotion for tumor cell motility
 inhibition, 72
Apoptosis-inducing factor (AIF), 67
Apoptotic
 cancer cell identification using fluorescent
 dyes, 324
 carcinoma cells
 L-PPMP-induced, 163
 identification by fluorescent dyes, 572
 drugs structure, 564
 signal transduction pathway, 41
APP, 59
Arginine residue in MPR 300, 262
Artificial radioactive species, 21
Artocarpin, 501
ASAL
 binding affinity, 529
 characterization, 526
 immunolocalization of, 526
Asialo-OSM. *See* AOSM
aSMase
 activation domain, 42
 translocation, 42
A-SMC, 331

- A-SMC proliferation stimulated by
MM-LDL, 334
POVPC, 334
- Asparagine-linked glycan. *See* N-glycan
- Aspergillus fumigatus*, cell wall of
biosynthesis, 239
pathobiology, 239
structure, 239
- Aspergillus wentii*, 239
- Assay for
A375-6 growth inhibition, 121
D10H.2 proliferation, 121
M1-3b growth inhibition, 121
PGE2 released from TIG-1 cells, 121
- ATF, 339
- ATF-1, 346
- Autoradiography, 181, 183
- Auxotrophic markers, 388
- Axonal transport, 55
- Azide labeling, 18
2,2-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) am-monium salt (ABTS), 531, 537
- B**
- B cell
lineage, 382
receptor signaling, 36
- BACE1
co-transfection of, 60
deficiency, 61
in Golgi apparatus, 60
- BACE1-induced
cleavage of ST6Gal I, 61
secretion of ST6Gal I, 61
- Bacillaceae, thermophilic, 435
- Bacterial glycosylation, 435
- Baculoviruses, recombinant, 554, 556
- Basic local alignment search tool (BLAST), 545
- BBMV
isolation, 526
proteins, non-deglycosylated, 527
receptor protein purification, 526
receptors characterization, 527
- Benign biliary duct diseases. *See* BBDD
- Beta elimination of O-glycosyl threonine linkage, 372
- Beta-secretase. *See* BACE1
- Betulinic acid (BetA), 565
- Biantennary sugar chains in hCG, abnormal, 473
- Bi-CRD galectins, 247
- Bile glycoprotein
HRP-lectin analysis of, 403
western blot of, 403
from extrahepatic bile duct carcinoma, 399
- Biological activity assays, 430
- Biologically active compounds in MM-LDL, 334
- Bio-Rad protein assay system, 135
- Biosynthesis pathways of nucleosidediphosphate sugars, 445
- Biotin-conjugated secondary antibody, 376
- Biotinylated lectins, 367
- Biotinylation of KM +, 502
- Blocking potency of P-selectin, 91
- Blood brain barrier (BBB), 515
- Blood groups indicated by lectin staining
BSA-IB4, 368
DBA, 368
HPA, 368
UEA-I, 368
- Bovine submaxillary mucin. *See* BSM
- BMC, 43
- Bone marrow cells. *See* BMC
- Bovine serum albumin. *See* BSA
- Brain
development, 267, 275
malformations, 292
- Brain infiltrating lymphocytes (BIL), 522
- Brain-specific transmembrane proteoglycan, 267.
See also NGC
- Brain tumor
animal model, 519
induction of, 516
regression mechanism, 515, 522
- Breast cancer cell growth in DxS, 465
- Breast carcinoma cells, 319
- 5-bromo-4-chloro-3-indolyl-N-acetylneuraminic acid. *See also* X-NANA
- Brush border membrane vesicle, 525
- BSA, 83, 342, 385, 399, 537
- BSM
acetate release from, 556
analysis, 531
de-O-acetylation of, 556
incubation, 557
- C**
- C. chrysell*, cell wall polysaccharides of, 242
- CA19-9 as tumor markers, 355
- Ca2+/calmodulin-dependent protein kinase II.
See CaMKII
- CaMKII
activity, intracellular, 50
as holoenzyme, 52
in dendritic architecture stabilization, 50
in neuronal plasticity, 52
- CaMKII signal
activation, 50
long-term effects of, 51
physiological aspects of, 51
short-term effects of, 50
- Camp response element. *See* CRE
- Camp response element-binding protein. *See* CREB
- Camp-dependent protein kinase. *See* PKA
- Cancer
serum diagnosis of, 355
sialylation of, 355
- Cancer cell
growth regulation, 158
invasiveness, 164
metastasis, 165, 403
morphology, 71
motility, 71
- Cancer therapy using CST genes, 175
- Cancer vaccine
from oligosaccharides, 413
sialooligosaccharides-based, 408
- Cancer-associated expression for sialyl Lewis A, 353
sialyl Lewis X, 353
- Cancer-associated mucins, 83
- Candidate gene approach, 295
- Capillary electrophoresis, 493
- Capillary endothelial cell
culture, 179, 180
glucose uptake in, 181
- Carbohydrate
specificity, 247
structures, 407
- Carbohydrate determinants, tumor-associated
alteration of
incomplete synthesis, 353
neosynthesis', 353
- Carbohydrate epitopes in tumors, 71
- Carbohydrate expression regulation
time-dependent, 151
tissue-specific, 151
- Carbohydrate ligands
for selectin, 360
sialyl Lewis A, 353
sialyl Lewis X, 353
- Carbohydrate recognition domain. *See* CRD
- Carbohydrate specific staining of receptors, 527
- Carbohydrate-binding
activity, 450
proteins, 119
specificities of lectins, 272
specificities, differences in, 249
specificity of galectin-4, 249
- Carbohydrate-carbohydrate interactions, 50
- Carcinoma cells
human, 157
apoptosis in anti-cancer drugs, 563
- Caspase
activation identification, 570
pathway activation, 566
- Caspase-3 activation
analysis, 163, 319
in SKBR3 cells, 322
western blot analysis of, 574
- Catalase, 112
- CD25 expression, 515
- CD4
crosslinking, 216
down-regulation, 64
expression, 64, 515
marker modulation, 522
signaling, 216
- CD44, 461
- CD44 downregulated by DxS, 467
- CD4-independent HIV entry, 214, 215
- CD82 effect on
cell adhesion, 73
haptotactic motility, 73
phagokinetic motility, 73
- CD82, molecular weight of, 74
- CD9
co-localization image, 75
for laminin-5-dependent cell motility inhibition, 75
- CD9 effect on
cell adhesion, 73
haptotactic motility, 73
phagokinetic motility, 73

- cDNA
 clones for MPR, 259
 encoding, 191, 557
 sequencing, 257
- CEA
 characterization, 526
 LC50 values of, 527
- Cell
 death, ceramide-induced, 159
 growth, 251
 harvesting, 159
 in neck region, 373
 lineage, 367, 373
 migration, 490
 motility, 193
 proliferation, 179
 synchronization, 159
 treatment, 194
 viability assay, 134
- Cell adhesion
 by selectins, 353
 GSL-to-GSL interaction-based, 76
 proteins, 65
 sialidase-based, 383
 sialoglycoconjugate-based, 383
- Cell adhesion inhibited by
 cytochalasin B, 383
 sialidase-specific inhibitors, 383
- Cell apoptosis triggering, 66
- Cell culture, 11, 121, 134, 159, 341
- Cell culture media on dextran inhibition, 463
- Cell culture treatment with
 photoactivable gangliosides, 21
 radioactive ganglioside, 21
- Cell incubation with
 lipoproteins, 332
 oxidized phospholipids, 332
- Cell invasion assay, 483, 486
- Cell mediated immune (CMI), 515
- Cell membrane permeability, 322
- Cell plasma membrane constituents
 gangliosides, 63
 sialic acid containing glycosphingolipids, 63
- Cell proliferation assay, 333, 463
- Cell specific regulation of GNT, 153
- Cell surface
 carbohydrates, 107
 gangliosides, 190
 glycoconjugates, 227
- Cell surface glycopeptide. *See* glycopeptide, cell
 peptide
 Cell wall
 fractionation, 240
 galactomannans, 239
 material preparation, 240
 polysaccharides FISS, 239
- Cell-associated HA
 chromatographic characterization of, 467
 degradation, 465
- Cell-cell adhesion by N-cadherin, 483
- Cell-cell interaction, 375
- Cellular differentiation, 367. *See also* glycans
- Cellular lipid microdomains, 35
- Central nervous system. *See* CNS
- Ceramide
 biosynthesis, 306
 formation, radioactive, 159
 in cell death, 579
 in signaling pathways, 39
 incorporating 14 C-Serine, 161, 571
 intracellular, 567
 moiety, 306
 source of GSL, 579
 transacylase activity, 25
- Ceramide galactosyltransferase. *See* CGT
- Ceramide metabolism
 ceramide-1-phosphate, 26
 ceramidephosphoethanolamine, 26
 cerebroside, 26
 sphingomyelin, 26
- Ceramide-utilizing enzymes, 27
- Cerebellar Purkinje neurons, 51, 54
- CGT, 339
- CGT gene, cloning of, 340
- Chaetosartorya chrysellata*, 239
- Chase incubation, 21
- Chelating
 activity, 140
 agents, use of, 137
- Chemical carcinogen ENU, 515
- Chemical shifts, 242
- Chemoattractant activity of ecalectin, 233
- Chemoenzymatic
 modified acceptors, 108
 synthesis, 112
- Chemokine receptor, 65, 216
- Chemokine receptor signaling, 218
- Chemotaxis, 218
- Chemotherapy, pre-operative, 564
- Chinese hamster ovary (CHO), 385
- Cholangiojejunostomy, 400
- Cholesterol lipid rafts generation, 33
- Chondroitin sulfate
 composition, 274
 disaccharide composition, 270
 of NGC, 274
 proteoglycan, 267
- Chondroitin-4-sulphate (C4S), 133
- Choriocarcinoma cell lines
 BeWo, 474
 JAR, 474
 JEG-3 cells, 474
- Chromatography
 anion-exchange, 119, 122
 high performance liquid, 399, 400
 lectin affinity, 475
 reverse phase, 475
 silica gel column, 14, 408
 size exclusion, 108, 250, 463
 thin layer, 11, 108, 193, 408
- Chromosomal S-layer glycan biosynthesis
 sequencing, 437
- Cis-platin (cis-DDP), 563, 564
- Cis-platin binding, 565
- Citrate-phosphate buffer, 378
- Classical plant lectins, 451
- Classical plant lectins in relation with
 non-classical, 457
- Cloning of ST3GalIII gene, 494
- CMD
 diagnostic criteria, 292
 role of glycosylation in, 293
- CMP, 199
- CNS, 49
- Coimmunoprecipitation
 approach, 67, 73
 of CD9, 75
- Colo-205 colonic cancer cells, 157, 159, 568
- Colo-205 treatment
 with betulinic acid, 563
 with cisplatin, 563
 with gd3 ganglioside, 563
 with L-PDMP, 563
 with L-PPMP, 563
 with PDMP isomers, 157
 with PPMP isomers, 157
 with tamoxifen, 563
- Colocasia tuber. *See* CEA
- Colorimetric assay, 84, 135
- Column chromatography
 for size analysis of oligosaccharides, 475
 on silica gel, 431
 uses, 13, 108, 111
- Complementarity determining regions. *See* CDR
- Complex N-glycans, 371
- Compounds with biological activity
 PEIPC, 335
 PGPC, 335
 POPVC, 335
- Concanavalin A (Con A), 99
- Congenital muscular dystrophy, defective
 glycosylation in, 291
- Congenital muscular dystrophy. *See* CMD
- Coomassie Brilliant Blue (CBB), 267
- Core 2 GlcNAc transferase, 151
- Coreceptor-binding sites, 215
- CRD, 91, 247, 545
- CRE
 functional role of, 339
 regulating hCGT gene expression, 339
 transcriptional elements, 340
- C-reactive proteins. *See* CRP
- CREB, 339
- Cross linking activity of galectin-4, 249
- Cross-linked proteins, 21
- CRP
 acute phase pentameric protein, 537
 analysis by fluorescence emission spectra, 540
 antibodies, binding diversity with, 539
 antibody binding with, 538
 anti-galactan reactivity of, 542
 by immunodiffusion, 542
 characterization, 538
 purification, 538
 tryptophan content of, 539
- CRP binding
 with asialofetuin, 540
 with fetuin, 540
 with fibronectin, 542
 with human IgG, 538, 539
 with plasma glycoproteins, 538
 with plasma glycoproteins, 539
 with sugars, 538
- Crude-membrane
 activity, inhibition of, 377
 fraction preparation methods, 376

- ¹⁴C-Serine incorporation in ceramide, 161, 571
 CST genes in cancer therapy, 175
 C-terminal sequence, 388
 Cucurbitaceae phloem lectin, 453
 Cytidine monophosphate. *See* CMP
 Cytoplasmic staining, 370
 Cytoplasmic/nuclear
 carbohydrate-binding proteins, inducible, 449
 localization, 452
 mannose-binding lectins, 454
 Cytoskeletal actin reorganization triggering
 ganglioside, 49
 protein kinase signals, 49
 Cytoskeleton, 213
 Cytosolic
 PLA2 activity, 26
 raft surface, 34
 sialidase, 191, 193, 377
 sialidase gene cloning, 383
 Cytotoxicity evaluation, 138
- D
 D10H.2 proliferation assay, 121
 DAB solution, 376
 DAB staining, 376, 382
 Datura stramonium agglutinin. *See* DSA
 Datura stramonium lectin. *See* DSL
 De novo biosynthesis of
 nonradioactive ceramide, 326
 radioactive ceramide, 326
 De novo synthesis of
 ceramide, 26, 42
 sialic acid, 202
 Deacetyl-lysoGD1b preparation, 14
 Deacetyl-lysoGM3 preparation, 14
 Death-inducing signaling complex. *See* DISC
 Defects in DGC, 291
 Defects in dystroglycan, 296
 Deglycosylated receptor protein, ligand blot
 analysis of, 527
 Degradative process, ganglioside, 307
 Dendritogenesis, 49, 52
 Densitometric scanning, 532, 538
 De-O-acetylation
 cellular receptors, 551
 of BSM, 556
 2-deoxy,2-acetamido- α -D-galactose, 373
 Deoxy-thymidine diphosphate (dTDP), 436
 Desialylation of OSM, 84
 Detergent-insoluble membranes. *See* DIM
 Detergent-resistant membrane. *See* DRM
 Developmental biology, 291
 Dextran sulphate. *See* DxS
 DGC
 defects in, 291
 in cell adhesion, 292
 in cell-cell signaling, 292
 in intracellular calcium concentrations, 292
 Diaminobenzidine staining. *See* DAB staining
 Dictyostelium discoideum, mannose-binding
 protein, 454
 Diffenbachia leaf (DEA)
 characterization, 526
 LC50 values of, 527
- Differentiation antigens, 367, 373. *See also*
 glycans
 Digital autoradiography, 13
 Digoxigenin enzyme assay (DIG), 531
 Di-isopropyl fluorophosphate (DFP), 555
 DIM, 33
 Dimerization, 207
 Diphenylene iodonium (DPI), 334
 Direct glycosylation processes, 309
 DISC, 66, 67
 Dimerization, 207
 Diphenylene iodonium (DPI), 334
 Direct glycosylation processes, 309
 DISC, 66, 67
 Disialosyl ganglioside
 cancer cell treatment, 321
 for regulating breast carcinoma cell death, 319
 GD1b, 319
 GD3, 319
 structures of, 320
 Disialosyl-gangliosides observed on
 breast carcinoma cells, 327
 colon carcinoma CELLS, 327
 lymphoma, 327
 melanoma, 327
 neuroblastoma, 327
 ovarian carcinoma cells, 327
 prostate, 327
 Dithiothreitol (DTT), 385
 DNA
 laddering analysis with apoptotic cancer cells,
 161, 570
 laddering assay, 563
 methylation, 353
 sequencing, 258
 synthesis inhibition, 564
 Dolichol-linked oligosaccharides, 181, 183
 Double-disruptant strain, 387
 D-PDMP, 331, 333, 566
 DRM, 33, 217
 Drosophila melanogaster gene, 549
 DSA, 399
 DSA lectin, 370
 DSL, 267
 D-threo-1-phenyl-2-decanoylamino-3-
 morpholino-1-propanol. *See*
 D-PDMP
 DxS
 anticoagulant properties of, 462
 concentration on HA degradation, 463, 465
 for HA degradation inhibition, 461, 469
 polyanionic nature of, 469
 DxS down-regulating
 CD44, 467
 HA synthase, 467
 DxS effect on
 CD44, 464
 HA synthase, 464
 HYAL 1, 464
 HYAL 2, 464
 DxS inhibiting
 enzymic degradation of high molecular weight
 HA, 466
 hyaluronidase activity, 463, 464, 465
 streptomyces HAase, 468
 testicular HAase, 468
 DxS on
 bovine testicular hyaluronidase activity,
 inhibitory effect of, 462
- exogenous Streptomyces hyalurolyticus,
 inhibitory effect of, 462
 human breast cancer cell morphology, 463
 human breast cancer cell proliferation, 463
 production of cell-associated HA, 463
 production of liberated HA, 463
 DxS up-regulating
 HYAL 1, 467
 HYAL 2, 467
 Dye-mixing assay, 218
 Dystroglycan, 292
 Dystroglycan glycoprotein complex. *See* DGC
- E
 EBDC
 pathological condition in relation with GnT
 activities, 402
 tissues, pathological conditions of, 400
 EBDC diagnosis with
 biochemical method, 400
 imaging diagnostic methods, 400
 EBDC, pathological subgroup-based
 differentiation grade, 402
 histological type, 402
 TNM stage, 402
 EBV, 375
 EBV-transformed B cells, 375
 Ecalectin gene transcription, 233
 ECL, 399, 400
 EGF
 binding affinity, 209
 inducing cell growth, 173
 receptor, 194
 signaling for anticancer therapeutics, 210
 signaling, 207
 EGF-induced ERK phosphorylation, 209
 EGFR
 activity, 49
 dimerization of, 209
 endocytosis, 209
 mutants, 208
 EGFR activation by
 EGF, 208
 TGF, 208
 Electrical energies composition
 dipole-dipole interactions, 548
 hydrogen bonding, 54
 Electrophoresis, 120, 526
 Electrophoretic mobility shift assay. *See* EMSA
 Electrophoretic mobility, 101, 268
 Electrophoretograms for ST3GalIII gene
 transcripts, 494
 Electrostatic interactions, 95
 Electrostatic potential of sugar-binding site, 549
 Elicitor activity, epoxyalkyl chain-length on, 428
 β -elimination, use of, 372
 ELISA
 analysis, protocols for, 409
 assays, 112
 auto reader, 122
 competitive, 84
 detection of 9-O-AcSG, 533
 direct, 84
 inhibition assay with mouse laminin, 110
 method, 257

- plates, 409
for SAA concentration measurement, 122
for serum IgG antibodies, 83
- ELISA inhibition results for
 α Gal analogues, 114
 α Gal epitope, 114
- Embryonic fibroblast cell, human, 121
- EMSA, 339, 342
- EMSA complexes identification, 344
- Endocytic vesicular trafficking, 582
- Endogenous
lectins, 228
membrane bound sialidase, 375
role of lectins, 452
- Endogenous GM3 enhancement. *See* GM3 enhancement
- Endoplasmic reticulum (ER), 39
- Enhanced chemiluminescence. *See* ECL
- ENU
chemical carcinogen, 515
receptor downregulation, 521
- Env, 213
- Envelope Glycoprotein. *See* Env
- Enzymatic
galactose oxidation, 18
oxidation procedure, 110
- Enzyme
activities related to sugar chain synthesis, 476
digestion, 475
- Enzymic HA degradative process inhibition. *See* HA, enzymic degradation of
- E-PHA, 399
- Epidermal growth factor receptor. *See* EGFR
- Epidermal growth factor. *See* EGF
- Epoxyalkyl (1 \rightarrow 3)- β -D-oligoglucosides
phytoalexin-elicitor activity, 427
protein-binding ability, 427
synthesis, 427
- Epoxyalkyl chain-length on elicitor activity, 428
- Epoxyalkyl glycosides, use of, 427
- Epoxybutyl-based glucopyranoside, 431
- Epoxypropyl-based glucopyranoside, 431
- Epoxypropyl-based glucopyranoside, 431
- Epstein-Barr virus. *See* EBV
- ERK phosphorylation, 64, 209
- E-rosette formation of microglia, 517, 520
- E-rosette-forming microglia, SEM study of, 517
- Erythrocyte binding antigen. *See* EBA
- Esterase assays, 554
- Esterification of sialic acid, 485
- Estrogen response element (ERE), 340
- Ethylene diamine tetra acetic acid (EDTA), 537
- Exogenous dolichol monophosphate, 182
- Exogenous gangliosides
as signal transducer molecules, 64
in human PBL, 64
- Extracellular matrix (ECM), 461
- Extracytoplasmic domain of MPR, 263
- Extrahepatic bile duct carcinoma. *See* EBDC
- Eye malformations, 292
- F
- FAB-MS, 408
- FACS
analysis of CD44, 467
microglial cells, 516, 520
synthase proteins, 467
use, 464
- Factor VIII C
biosynthesis, 181
glycosylation, 179
immunoprecipitation, 183
N-glycosylation, 186
- Falcon Microslide System, 322
- Fas
crosslinking, 41
signaling, 67
stimulation, 42
- Fas-associated death domain (FADD), 66
- Fas-induced apoptosis, 40, 582
- Fast atom bombardment mass spectra. *See* FAB-MS
- Fast performance liquid chromatography. *See* FPLC
- Fatty acid, 27
- FBS, 120
- FCMD
chromosomes, 293
mutation, 293
- FCMD patients
hypotonia, 293
mentally retardedness, 293
muscle weakness, 293
- FCMD, brain malformations in
cerebellar micropolygyria, 293
cerebral micropolygyria, 293
- Fetal bovine serum. *See* FBS
- Fetal calf serum (FCS), 552
- FGF
bioactivity of, 385
by CHO cells, 386
secretion from kidney cells, 396
signal intensity of, 390
sugar chains of, 385
tissue distribution of, 385
- Fibroblast growth factor. *See* FGF
- Fibroblasts treated with GAG, 139
- Fibronectin-dependent cell adhesion, 73
- Fisherbrand nylon filter, 110
- FITCVT1B, 33, 34, 35
- FKRP, 295
- Flow cytometry, 171, 517, 531, 532, 533
- Fluorenyl
deprotection, 18
protection, 21
- 5-fluoroorotic acid (5-FOA), 385, 389
- Fluorescein isothiocyanate (FITC), 531, 532
- Fluorescein-labeled verotoxin 1 B subunit. *See* FITC-VT1 B
- Fluorescence
emission measurement, 539
laser scanning confocal microscopy, 75
microscopy, 554, 572
spectrofluorimeter, 538
spectroscopic analysis, 538
- Fluorescence Activated Cell Sorter Analysis. *See* FACS
- FACS
Fluorescence staining
of PSS-380, 570
- Propidium Iodine, 570
- Fluorescent dye
for apoptotic carcinoma cell identification, 572
for membrane phosphatidylserine translocation, 574
- Fluorescent microscope with UV filter, 376
- Focal adhesion kinase (FAK), 50, 218
- Focal de-differentiation site, 71
- FPLC
affinity chromatography, 100
system, 120
use, 109
- Fractional synthesis rate. *See* FSR
- Free radicals
generation, 133, 134, 137
source, 462
- FSR
calculation, 101
of AGP-glycoforms, 102
- Fucoidan, 91
- Fucose-binding protein
3-D structures of, 545, 546
interaction with ligands, 545
- Fucose binding site, 94
- Fucose transfer steps, 356
- Fucosylglycan-binding lectins, 275
- Fucosyltransferases, gene encoding, 356
- Fukutin mRNA transcripts, 294
- Fukutin-related protein (FKRP), 291
- Fukuyama Congenital Muscular Dystrophy. *See* FCMD
- Functional lectinomics, 228
- Fungi, 239
- G
- GAG
antioxidant properties of, 133
effects on cell viability, 137
on fibroblast glutathione activity, 138
origin, 134
reducing oxidative damage, 133
statistical analysis, 135
structure, 133
sulphated
chondroitin sulphates (C4S and C6S), 133
dermatan sulphate (DS), 133
heparan sulphates (HS), 133
keratan sulphate (KS), 133
- α Gal analogues preparation, 112
- α Gal epitope
ELISA inhibition for, 114
immobilized, 110
role of, 112
- α Gal trisaccharide analogues, 116
- Galactomannan
cell wall, 239
structure of, 240
- Galactomannan different from *Aspergillus wentii*, 239
Chaetosartorya chrysella, 239
- Galactose
receptors, 395
transfer steps, 358
- Galactose oxidase. *See* GAO

- Galactose-1-phosphate uridylyl transferase (GALT), 359
- Galactose-specific lectin, 382. *See also* Mac-2 antigen
- Galactose-specific orthologs, 457
- β -Galactosides, 227
- Galactosylation of ceramide, 40
- Galactosylceramide, 579
- Galactosyltransferase, 107, 331
- β 1,3-galactosyltransferase, 358
- α 1,3-Galactosyltransferase assay, 109
- Galatocerebroside. *See* GalC
- GalC, 339, 340
- GalE activity, 110
- Galectin
- cytoplasmic interaction, 232
 - gene transcription, 230, 233
 - homodimeric, 233
 - in colon cancer cells, 227
 - inhibitor, 253
 - isoforms, 230
 - sequence coding, 231
- Galectin expression modulation, 234
- Galectin fingerprinting
- by RT-PCR, 228
 - transfer, 230
- Galectin-4
- as diagnostic marker, 252
 - blocking activities of, 253
 - carbohydrate-binding specificity, 249
 - cross linking activity of, 247, 249
 - expression patterns, 251
 - for anti-cancer drug development, 252
 - gene regulation, human, 251
 - immunohistochemical detection of, 248
 - mRNA identification, 248
 - nuclear localization of, 251
 - on cell growth, 252
 - properties of, 247
 - synthetic inhibitors of, 250
- Galectin-4 in
- cancer tissues, 247, 252
 - gastrointestinal mucosa, 252
 - human malignancies, 250
 - normal tissues, 247, 252
- Galectin-4-mediated cell adhesion, 252
- Galectin-6 detection, 248
- Galectins, complex subfamily of, 231
- GalNAc, 49, 371, 399
- GalNAc signal
- long-term effects, 54
 - on dendritic formation, 54
 - short-term effects, 52
- α 1,3GalT
- acceptor specificity assay for, 109
 - acceptor specificity for, 113
 - from transformed E.coli strains, 109
 - purification, recombinant, 109
- GalT activity determination, 475
- GalT-2 activation, 331, 333, 335
- α 1,3GalT-catalyzed synthesis, 108
- β 1,4GalT-4
- activity modulation, 163
 - assay of, 160
- GalT-4 activity, 567
- Ganglioside
- biology basics, 302
 - catabolism, 307
 - chemical structure of, 302
 - chemistry basics, 302
 - de novo biosynthesis, 306
 - degradation, 44, 310
 - derivatives, photoactivable, 11
 - derivatives, radioactive, 11
 - ganglioside mediated signal transductions,
 - comparison of, 55 GM3, 43, 169
 - metabolic events, intracellular sites of, 311
 - metabolic salvage, 310
 - metabolic turnover evaluation, 311
 - metabolism, 301
 - mixture, 322
 - oligosaccharide, biosynthesis of, 313
 - photolabeling, 13
 - radioactivity in, 310
 - recycling, 311
 - regulating EGF signaling, 210
 - schematic formulas of, 304
 - sialidases, 192
 - tritium-labeling, 14
- Ganglioside derivative synthesis
- [³H]NaBH₄ reduction, 21
 - alkaline hydrolysis, 14
 - Azide labeling, 18
 - enzymatic galactose oxidation, 18
 - fluorenyl deprotection, 18
 - fluorenyl protection, 21
 - N-acetylation, 18
 - N-acylation, 14
- Ganglioside in
- breast cancer initiation, 328
 - caspase-cascade activation initiation, 328
 - normal cell death, 328
 - pathological processes, 43
 - signal transduction, 328
- Ganglioside regulating
- cell signaling, 43
 - receptor function, 173
- Ganglioside turnover
- endocytotic route flow, 305
 - exocytotic route flow, 305
 - metabolic fluxes, 305
 - metabolic pathways, 305
 - plasma membrane turnover rate, 305
- Ganglioside-mediated protein kinase modulation, 49, 50
- Ganglioside-protein interactions, 11
- Gangliosides, intercellular trafficking of
- de novo biosynthesis, 301
 - direct glycosylations, 301
 - endosomal level degradation, 301
 - enzyme-assisted chemical modifications, 301
 - plasma membrane recycling, 301
 - waste products degradation, 301
- GAO
- for enzymatic oxidation, 110
 - reaction, 21
 - use, 107
 - utilization, 111
- GAPDH, 385, 388, 390
- Gas chromatography combustion isotope ratio mass spectrometry. *See* GC-c-IRMS
- Gastric mucosa
- human, 367
 - microanatomical structures of, 367
- Gastrointestinal mucosal defense, 252 Gb3
- in HIV/host cell fusion, 36
 - receptor function, 35,
- Gb3-containing rafts, 36
- GC mutagenic primer, 341
- GC-box
- binding proteins, 344
 - functional role of, 339
 - transcriptional elements, 340
- GC-c-IRMS
- for measuring KIV enrichments, 101
 - use, 99
- GD3
- and mitochondria, 581
 - antigen, 39
 - gangliosides, 320
 - role in apoptosis, 581
 - trafficking to mitochondria, 582
- GD3-induced apoptosis
- mechanisms, 40
 - signaling pathway of, 42
- Gel electrophoresis, 484
- Gel permeation chromatography, 183, 475
- Gel-filtration for mucin subunit, 88
- GEM, 33, 50, 55, 63, 64
- GEM in
- lipid sorting, 65
 - regulating integrin function, 65
 - signal transduction, 65
 - T cell activation, 65
 - T cell apoptosis, 66
 - TCR signaling, 66
- Gene disruption method using Salmonella hisG gene, 389
- Gene expression control mechanism, 176
- Gene isotranscripts, 493
- Gene silencing by
- DNA methylation, 356
 - histone deacetylation, 356
- Genetic linkage analysis, 296
- Genetic mutation methods, 207
- Geobacillus stearothermophilus*, 436
- GF/A filtering for radioactivity incorporation, 321
- GlcCer synthase, 42
- GlcNAc, 267, 399, 473
- GlcNAc 6-sulfation, 355, 356
- β -1,6-GlcNAc transferase. *See* GnT
- GlcNAc transfer steps, 358
- GlcNAc2Man3GlcNAc2-PA, 400
- Glioma model, 515
- Globotriaosyl ceramide. *See* Gb3
- Glomerular basement membrane, 395
- Glomerular filtration, 395
- GLS-containing lipid microdomains, 36
- Glucan- binding
- assay, 430
 - protein of soybean assays, 427
 - sites, affinity measurement at, 428
- Glucopyranoside
- epoxybutyl-based, 431
 - epoxypropyl-based, 431
 - epoxypropyl-based, 431

- Glucose transport, 179
- Glucosylceramide
synthase inhibitors, 30
synthase inhibitors, pharmacology of, 25
synthase, 26, 579
use, 39
- Glutathione assessment, reduced, 135
- Glycan
biosynthesis, 435
complex patterns, 371
defined, 367
structure in bile glycoproteins, 399
structure in tissue, 399
- Glycan analysis, N-cadherin, 485
- Glycan chain analysis by MALDI MS, 486
- Glycan chains, polymorphic variations, 154
- Glycan-moieties, 268
- Glyceraldehyde-3-phosphate dehydrogenase.
See GAPDH
- Glycerolipids in cell signaling, 25. *See also*
ceramide metabolism
- Glyco-chain dependent signaling, 61
- Glycoconjugate
and saccharides, 84
cancer vaccines, 407
cell surface, 435
immunogenicity of, 410
PAA-based, 83
sialic acid loading, 409
synthetic pathway, 360
- Glycoforms of α 1-acid glycoprotein, 99
- Glycohistochemical technique, 228
- Glycolipid
biosynthetic pathways, 64
in kidney, 154
polymorphic differences, 151, 154
- Glycolipid-enriched membranes. *See* GEM
- Glycopeptide T11TS/SLFA-3 preparation, 516
- Glycopeptide, cell peptide, 515
- Glycoprofiling, 367
- Glycoprotein
acute phase, 99
cell surface, 189
detection with HRP-labeled lectins, 401
from cancer cells, 400
in cancer tissues, 399
in signal transduction, 207
regulation by Gsl5, 153
using mammalian cells, disadvantages of, 385
- Glycoprotein glycans, 367
- Glycoprotein T11TS, 515
- Glyco-receptors, 55
- Glycosaminoglycans. *See* GAG
- Glycosidic linkages, 535
- Glycosignaling domain in human PBL, 64
- Glycosphingolipid regulating gene-5. *See* Gsl5
- Glycosphingolipid. *See* GSL
- Glycosphingolipid-enriched domain. *See* GEM
- Glycosylated human interleukin-1 α synthesis,
119
- Glycosylated CRP. *See* CRP
- Glycosylated IL-1 α . *See* Neu5Ac-Gal-IL-1 α
- Glycosylated secFGF, comparison with
non-glycosylated, 395
- Glycosylation
affecting protein structure, 180
congenital disorders of, 185
defining cancer cell motility, 71
defining invasiveness, 71
gene cluster, 435
in congenital muscular dystrophy, 291, 293
in tumor metastasis, 71
in tumor progression, 71
post-translational, 103
processes, direct, 309
S-layer, 435
- Glycosylation effect on
biological activities, 119
integrin interaction, 73
Tsp, 73
- Glycosylation, qualitative analysis of, 532
- Glycosylphosphatidylinositol. *See* GPI
- Glycosyltransfer reactions, steps of
fucose residues, 356
galactose transfer, 356
GlcNAc transfer, 356
sialic acid addition, 356
- Glycosyltransferase
as physiological substrate, 59
genes, 172
physiological role of, 207
sequences, 296
- Glycosyltransferase-transfectants, 207
- Glycotope, molecular characterization of, 534
- GM3
inhibiting tumor cell motility, 72
treatment, 64
- GM3 complex for laminin-5-dependent cell
motility inhibition, 75
- GM3 enhancement, 175
- GM3-enriched microdomains, role of, 63
- GM3-induced down-modulation, 64
- GnT
activities in relation with pathological
conditions, 402
activity control, 152
activity determination, 475
assay of, 400
gene, 5'-upstream sequence of, 153
genomic composition of, 153
pattern of EBDC, 403
regulation by Gsl5, 153
with HRP-lectins, histochemical study on, 402
- Goat MPR 300, molecular cloning of, 259
- Goat MPR 46, molecular cloning of, 262
- Goat receptors. *See* MPR
- Golgi
apparatus, 59, 301, 306, 579
glycosyltransferases, 60
membranes, 163
- GPI, 11, 63, 200
- GPI-anchored proteins, 65
- Green fluorescent protein (GFP), 553
- Growth factor signaling, 207
- GSL
and cell adhesion, correlation between, 172
and mitochondria, 579
and multidrug resistance, 583
as proapoptotic lipids, 582
binding, 36
biology basics, 302
biosynthesis, 39, 157
biosynthesis, inhibitors of, 159, 163
chemistry basics, 302
glycosyltransferases, 568
governing gene expression, 169
in cancer therapy, 582
in cell death, 39
in cell signaling, 583
in disease, 583
location of, 302
metabolic turnover evaluation, 311
neutral, 302
pattern, 313
radioactive, 160
radioactivity analysis, 568
radioactivity distribution in, 321
radioactivity extraction, 568
receptor activity, 33
receptor regulation, 36
recycling, 311
salvage pathways, 301
schematic formulas of, 304
shedding, 43
signaling, 301
structure, 39, 169
synthesis, 567
synthesis topology, 40
treatment for cancer cells, 321
with anti-apoptotic properties, 42
- GSL as binding sites
for bacteria, 39
for viruses, 39
- GSL domains (rafts), HIV receptors in, 215
- GSL in
CD4-dependent HIV entry, 214
CD4-independent HIV entry, 215
HIV signaling, 213
HIV transcytosis, 214
microdomain, 175
pathogenesis, 213
- GSL located at
Golgi complex endosomes, 39
plasma membrane, 39
- GSL turnover, 305. *See also* ganglioside turnover
- Gsl5
for GNT regulation, 153
gene identification, 151
GSL-dependent cell adhesion, 76
- GSL-HIV envelope interactions, 213
- GT1b signal
long-term effects of, 51
physiological aspects of, 51
short-term effects of, 50
- Guanosine diphosphate (GDP), 436
- H
- HA
assay, 463
degradation by DxS concentration, 465
depolymerization of, 470
enzymic degradation of, 466
hydrolysis, 463
metabolites, 469

- molecular weight, characterization of, 462, 464
 synthesis, 461
- HA degradation inhibition
 by dextran sulphate
 in vitro study, 461
 in vivo study, 461
 cell-associated, 465
 liberated, 465
- HA synthase expression downregulation by DxS, 467
- HAase inhibitor, 468
- H-antigen, 372
- Haptotactic motility, 73, 74
- Hase method, 400
- hcg, 473
- hCG purification, 475, 476
- hCGT
 gene expression, 339
 gene promoter, 343, 347
 promoter generation, 340
 transcription regulation, 348
- HeLa cells, 555
- Hemagglutination inhibition assays, 532
- Hemagglutinin-esterase (HE)
 GFP proteins, chimeric, 556
 proteins, viral, 551, 554
- Hematology, 122
- Hematoxylin-eosin staining, 381
 corticomedullary regions, 381
 medullary regions, 381
- Hemolytic uremic syndrome, 34
- Heparin-Sepharose chromatography, 388
- Hepatic glycosylation process, 99
- Hepatoblastoma cells, 582
- HG-APEA, 430
- High mannose N-glycans restricted to
 chief cells of glands, 371
 neck cells of gland, 371
- High performance liquid chromatography. *See* HPLC
- High-mannose type oligosaccharides, structure of, 390
- Histochemical active staining of sialidase-positive cells, 380
- Histochemical staining using
 HRP-DSA, 400
 HRP-E4-PHA, 400
- Histochemical studies on GnT products, 402
- Histone deacetylation, 353
- HIV entry
 aspects, 214
 CD4-dependent, 214
 CD4-independent, 215
 infection, 213, 215
 pathogenesis, 213, 214
 receptors in GSL domains, 215
 receptors, signal properties of, 216
 signaling effects, 219
 signaling, GSL in, 213
 transcytosis, 214
- HIV-1
 entry, 218
 signaling and entry, 218
- HNK-1
 carbohydrates, 275
- epitope on NGC, 275
- HOG cells, 341
- Homogenisation of melanoma cell lines, 484
- Homology modeling, knowledge-based, 546
- Homopteran insects, sap-sucking
 aphids, 525
 leafhoppers, 525
- Horse radish peroxidase. *See* HRP
- HPLC
 for preparing GlcNAc2Man3GlcNAc2-PA, 400
 method for GnT activities, 399
 use, 11
- HRP, 399, 531, 537
- HRP-labeled
 DSA, 399
 lectins for detecting glycoproteins, 401
- HRP-lectin analysis of bile glycoproteins, 403
- HSA, 83
- HSPC, 101
- Human
 antibodies purification, 84
 fibroblast cultures, 133
 foetal brain gangliosides, 496
 galectin-4 gene regulation, 251
 IgG, differential binding with, 539
 LDL preparation, 332
 melanoma cell line, 483
 oligodendroglioma, 339
 UDP-galactose, transcriptional regulation of, 339
- Human breast cancer cells. *See* SKBR3 cells
- Human breast carcinoma cells. *See* SKBR3 cells
- Human ceramide galactosyltransferase. *See* hCGT
- Human chorionic gonadotropin. hCG
- Human colon carcinoma cells. *See* Colo-205
- Human CRP. *See* CRP
- Human ganglioside, 382. *See also* plasma membrane
- Human gastric mucosa, lectin histochemical study, 367
- Human neuroblastoma. *See* LAN-5
- Human PBL, 64, 66
- Human peripheral blood lymphocytes. *See* human PBL
- Human serum albumin. *See* HSA
- Human serum protein calibrator. *See* HSPC
- Human study protocol, 100
- Human T lymphocytes, 63
- Human umbilical vein endothelial cell. *See* HUVEC
- HUVEC
 HUVEC 385, 386
 HUVEC proliferation activities of secFGF, 392
- HYAL upregulation by DxS, 467
- Hyaluronan synthase proteins. *See* HAS
- Hyaluronan. *See* HA
- Hyaluronic acid, 133
- Hyaluronidase
 activity inhibition by DxS, 464
 activity, 462
 protein (HYAL), 461
- Hybridization, in situ, 194, 248
- Hydrazinolysis using Hydraclub, 389
- Hydrogen bond, 95
- Hydrogen bonding between protein and sugar, 548
- Hydrolysis of
 phosphatidylcholine, 31
 phosphatidylethanolamine, 31
- Hyperacute rejection (HAR), 107
- Hypersialylation, 204
- Hypoglycosylation, 293
- Hypoxia-inducible factors (HIF), 353, 360
- I
- Ig. *See* Immunoglobulin
- IgG antibodies, 87
- IgG binding, 537
- ¹²⁵I-IL-1 α
 binding assay, 121
 competitive binding of, 124
- IL-1
 benefits of, 119, 129
 development, 119
 inducing SAA in mice, 124
 inducing serum NOx in mice, 124
 proliferative effect on T cells, 124
 radiolabeling of, 122
 receptor, types of, 120, 127
 stimulation of PGE2 production, 124
 treatment on serum glucose level in mice, 124
- IL-1 α
 recovering WBC, 125
 tissue distribution of, 126
 treatment in 5-fluorouracil-treated mice, 125
- IL-1 antiproliferative effect on
 melanoma cells, 124
 myeloid leukemic cells, 124
- IL-1R
 binding affinities, 128
 molecular weight of, 127
- ImageMaster System, 401, 403
- Immune effector cell of brain, 519
- Immune response
 anti-inflammatory, 522
 pro-inflammatory, 522
 of antibody isotypes
 IgG1, 407
 IgG2a, 407
 IgG3, 407
 IgM, 407
- Immunopotential of microglia, 517
- Immunization of mice, 409
- Immunoaffinity column chromatography, 267, 269, 270
- Immunoaffinity method, 257
- Immunoblotting, 293
- Immunochemical staining of thymus, 380
- Immunodetection of N-cadherin, 485
- Immunodiffusion, 101
- Immunodominant epitopes, 542
- Immunodominant sugar, 108
- Immunoelectron microscopy, 582
- Immunoelectrophoresis, 101
- Immunofluorescence
 for galectin-4, 248
 staining, 191
- Immunogenicity
 of carbohydrate, 119
 of derivatized glycoconjugates, 407, 410
- Immunoglobulin, 375

- Immunohistochemical
 double staining, 383
 techniques for MEB, 294
- Immunohistochemical analysis
 for galectin in cancer cells, 234
 of galectin-4 protein expression, 250, 252
- Immunolocalization
 analysis, 525, 527
 of ASAL, 526
- Immunological properties of Neu5Pr, 410
- Immunomodulatory property of T11TS, 518
- Immunophenotyping, 515, 516, 517
- Immunoprecipitation
 for NGC purification, 267
 of MAP kinase, 333
 of N-cadherin, 483, 484
 of NGC, 269
 with anti-GM3, 65
- Immunoreactive materials, 270
- Immunoreactivity of NGC, 272
- Immunoreceptors
 B-cell receptor, 68
 FcRs, 68
 TCR, 68
- Immunostaining, 270, 375
- In situ digestion, 485
- In situ hybridization, 194, 248
- Incomplete synthesis
 carbohydrate determinants, 353
 in sialyl Lewis X/A, 353
- Inducible cytoplasmic/nuclear
 carbohydrate-binding proteins, 449
- Infectious salmon anemia virus (ISAV), 551
- Inflammatory breast cancer (IBC), 564
- Inhibitors, effects of, 377
- Insect bioassay in artificial diet, 526
- Insulin
 down-regulating cell proliferation, 185
 on factor VIIIIC, 186
 on glucose uptake, 184
 treated cells, 183
 upregulating lipid-linked
 oligosaccharide-PP-Dol, 179
- Insulin receptor. *See* IR
- Insulin-mediated
 cell growth, 180
 oligosaccharide-PP-Dol biosynthesis, 182
- Integrin expression regulation by SM3, 170
- Integrin $\alpha 3$ for laminin-5-dependent cell motility
 inhibition, 75
- Integrin receptor, 73
- Integrin/tetraspanin complex for tumor cell
 motility inhibition, 72
- Interleukin 1. *See* IL-1
- Intermediate filaments (IF), 312
- Intestinal intraepithelial lymphocytes (IEL), 356
- Intracellular
 galactose metabolism alteration in cancer, 358
 protein kinase activities, 51, 53
 signal-generating system, 51
- Intralysosomal
 degradation of glycosphingolipids, 308
 sialidase, 190, 377
- Intralysosomal type enzyme, 377
- IODO-BEADS Iodination, 389
- Ion-exchange chromatography, 517, 527
- IR
 and N-glycan, 210
 heterodimer, 210
- Isoelectric Focusing (IEF), 527
- Isoenzymes in
 colon, 355
 epithelial cells, 356
- J
- Jacalin-related lectins, 457
- Jack bean. *See* JB
- Jasmonate-induced chitin-binding, 449
- JB, 473
- JEG-3 cells
 for abnormal biantennary structure formation,
 474
 usefulness of, 473
- K
- Ketoisovalerate (KIV), 101
- [1-¹³C]ketoisovalerate determination, 101
- Keyhole limpet hemocyanin. *See* KLH
- Kidney tubular cell-specific regulation, 151
- Kidney-specific core 2 GlcNAc transferase, 151
- KLH, 407
- KLH conjugates, immunological studies on, 411
- KM +
 biotinylation of, 502
 carbohydrate specificity of, 502
 lectin, 501
 ligands detection, 502
 purification, 502
 staining inhibition, 502
 staining intensity, 502
 staining quantification, 502
 western blotting for, 505
- Koenigs-Knorr condensation method, 428
- L
- LacCer, 164, 169, 331, 334
- Lactate dehydrogenase. *See* LDH
- Lactosylceramide. *See* LacCer
- Lactosylsulfatide. *See* SM3
- Laminin-5-dependent cell motility inhibition by
 CD9, 75
 GM3 complex, 75
 integrin $\alpha 3$, 75
- L-arabinose binding protein of *E. coli*, 549
- LARGE Gene, 296
- Laser confocal microscopy, 582
- Laser induced fluorescent capillary
 electrophoresis, 494
- LCAT, 25, 29
- LCAT-like lysophospholipase (LLPL), 28
- LDH, 133, 135, 138
- LDH assay, 135
- LDL, 331
- Leafhoppers, 525, 526
- Lecithin cholesterol acyltransferase. *See* LCAT
- Lectin
 ASAL, 525
 binding, 202, 370, 372
 binding to gut epithelial membrane, 525
 CEA, 526
 cucurbitaceae phloem, 453
 DEA, 526
 endogenous, 228, 452
 extraction by affinity chromatography, 526
 histochemical staining, pattern of, 373
 identification, 453
 jacalin-related, 457 KM +, 501
 LC50 values of, 525
 legume, 450
 like property, 537
 marker for secretory canaliculi, 372
 polyspecific, 459
 purification by affinity chromatography, 526
 receptor interaction, 525
 Seed, 451
 sugar binding properties of, 368
 toxicity determination of, 527
 treated insects, 525
 X-ray crystallography analysis of, 451
- Lectin affinity blotting, 502, 503
- Lectin affinity chromatography, 475, 506
- Lectin histochemistry
 effectiveness, 501, 502
 histochemistry, plant, 228
 of human gastric mucosa, 367
- Lectin reactivity of NGC, developmental changes
 in, 272
- Lectin staining
 level, change in, 371
 patterns of normal human gastric mucosa, 369
 patterns, 372
 of normal human gastric tissue
 BSA-IB4-stained surface, 370
 BSA-II-stained glands, 370
- Lectin staining intensity
 just detectable, positive, 368
 moderately positive clear, 368
 negative, 368
 strongly positive, 368
- Lectin-blot analysis, 267, 270, 501
- Lectin-negative plants, 450
- Lectinomics, functional, 228
- Lectin-reactivity of NGC, comparison with
 neurocan, 272
 phosphacan, 272
- Lectins, origins of
Dolichos biflorus, 368
Galanthus nivalis, 368
Griffonia simplicifolia, 368
Lens culinaris, 368
Limax flavus, 368
Maclura pomifera, 368
Narcissus pseudonarcissus, 368
Phaseolus vulgaris, 368
Pisum sativum, 368
Solanum tuberosum, 368
Wisteria floribunda, 368
- Lectin-specific antibodies, 228
- Legume lectins, 450
- Leishmania donovani, sialic acid adsorption in,
 202
- Lewis acid catalyst, 427, 428
- Lewis antigens, 154
- LGALS, 251

- LGMD, clinical features of
 proximal limb muscle wasting, 295
 proximal limb muscle weakness, 295
- Liberated HA
 chromatographic characterization of, 467
 degradation, 465
- Ligand
 binding, 207, 208, 209, 262, 537
 blot analysis, 526, 527
 blot assay of BBMV proteins, 527
 derivatization, 234
 lipid transfer, 580
- Limb-girdle muscular dystrophies. *See* LGMD, clinical features of,
- Lipid domains, 11
- Lipid hydroperoxides, 138
- Lipid microdomains
 detergent-resistant, 33
 GLS-containing, 36
- Lipid peroxidation analysis, 133, 135, 137
- Lipid-linked oligosaccharide, 179
- Lipophilic compounds, 99
- Liquid nitrogen trap, 13
- Liquid scintillation counter, 109, 333
- Liquid scintillation spectrometer, 183
- Liver
 fibrogenesis, 583
 natural killer T cells (NKT), 583
- Liver-specific gene expression, 251
- LLO
 precursor, 185
 synthesis, down-regulation of, 180
 synthesis, upregulation of, 180
 up-regulated by insulin, 179
- Low density lipoprotein. *See* LDL
- Low-density membrane microdomains, 76
- Lowry's method, 400
- Lowry's method use for KM +, 503
- LPLA2, 25
- Luciferase reporter plasmid constructs, 340
- Lymphocytes, interaction of, 375
- Lymphoproliferation assay, 535
- Lysogangliosides, synthesis of, 14
- Lysoglycosphingolipids, 308
- Lysophospholipase activity, 29
- Lysosomal
 degradation, 309
 membrane sialidase, 377
 membrane, 190
 phospholipase A2 identification, 25
 sialidase, 191, 194
- Lysosomal phospholipase A2. *See* LPLA2
- M
- M. musculus*, 154
- M1-3b cell growth inhibition, assay for, 121
- MAb, 267, 342, 375
- Mac-1
 antigen, 375
 in mouse thymus, 375
 β 2integrin, 382
 on granulocytes, 382
 on large granular lymphocytes, 382
 on macrophages, 382
 on monocytes, 382
- Mac-2 antigen, 382
- MAG, 50, 347
- MALDI MS
 for N-cadherin, 485
 performing glycanchain analysis, 486
 spectras, analysis of, 485
- MALDI-TOF, 473
- MALDI-TOF analysis, oligosaccharides, 240
- MALDI-TOF/MS, 473, 476
- Malignant choriocarcinoma disease, diagnosis of, 473
- Malignant properties of sialylation
 invasiveness, 189
 metastatic potential, 189
- Malignant transformation, 403
- Malondialdehyde (MDA)
 analysis for lipid peroxidation, 139
 determination, 135, 137
- Mammalian cell culture system, disadvantages of
 complicated handling requirements, 385
 contamination risk by prion, 385
 high culture cost, 385
- Mammalian genes encoding galectins. *See* LGALS
- Mammalian sialidase
 functions of, 191
 molecular cloning, 194
 transfection, 195
- Man, 267
- β Man-SC6H4NO₂, molecular modeling of, 92
- α -Man'ase II, 473
- α -Man'ase II activities determination, 475
- Mannose 6-phosphate receptors. *See* MPR
- Mannose receptors, 395
- Mannose. *See* Man
- Mannose-binding lectin. *See* Oryzata
- Mannose-binding protein. *See* MBP
- Mannose-containing receptors, 454
- Mannose-type sugar chain, 385. *See also* fibroblast growth factor, tissue distribution of α -mannosidase II. *See* α -Man'ase II
- Mannosides
 monomeric, 93
 multivalent, 93
- Mannosyl-glycoconjugates, 501
- Mannosylphospho-dolichol. *See* Man-P-Dol
- Manp linkages, 244
- Man-P-Dol, 181
- Man-P-Dol synthase
 assay for, 181
 of dolichol pathway, 184
- Man-specific lectin in
 hepatocytes, 129
 macrophages, 129
- MAP kinase activity
 by phosphorylation, 333
 immunoprecipitation of, 333
 measurement, 333
- Mass spectrometry use, 559
- Matrigel invasion chamber assay, 486
- Matrix-assisted laser desorption ionization mass spectrometry. *See* MALDI MS
- Matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *See* MALDI-TOF/MS
- Matrix-assisted laser desorption ionization time-of-flight. *See* MALDI-TOF
- MBP, 91, 340
- MDC1, 292, 295
- MEB
 gene MAPPING, 294
 screening method for, 294
- MEB causing
 brain abnormalities, 294
 congenital glaucoma, 294
 eye myopia, 294
- Melanoma cell lines
 from metastatic sites, 490
 homogenisation, 484
 in vitro migration of, 484
- Melphalan, anti-cancer drugs, 563
- Membrane
 fusion, 213
 rafts, 213
- Membrane phosphatidylserine translocation detection, 322, 574
- Membrane topology analysis, 191
- Membrane-bound sialidase, 192
- Metabolic
 events at plasma membrane level, 309
 salvage process, 310
- Metabolic pathways of
 gangliosides, 306
 glycosphingolipids, 306
- Metastasis, 227
- Metastatic potential, sialidase, 193
- Methylation analysis, 239
- 4-Methylumbelliferyl-N-acetyl- α -D-neuraminic (4MUNeu5Ac), 376
- MHC class II antigen, 381, 515
- Microbial sialidases, 192
- Microcolumn clean-up of sugar, 485
- Microglia
 cell isolation, 516
 E-rosette-forming, 516
 immune profile of, 515
 immunopotential of, 517
 receptor modulation of, 516
- Micromolar gangliosides, 52
- Microorganisms and culture media, 240
- Minimally modified LDL. *See* MM-LDL
- Mitochondria
 and GD3, 581
 GD3 trafficking to, 582
- Mitochondrial
 membrane permeabilization, 583
 permeability transition pore (MTP), 41
 signaling pathway (MSP), 563
- Mitogenic activity, 386
- MM-LDL
 effects of, 332
 for aortic smooth muscle cell proliferation, 331
- MM-LDL-stimulated cell proliferation, 334
- MOG, 339, 348
- Molecular binding assays, 275
- Molecular cloning, 204, 257
- Molecular dynamics, 546
- Molecular mechanism for
 GNT control, 152

- sialyl Lewis A cancer-associated expression, 353
sialyl Lewis X cancer-associated expression, 353
- Molecular modeling, 545
- Monoclonal
anti-AGP IgG, 99
antibody Mac-2, 376
anti-CD2 antibody, 520
anti-NGC antibody, 268
- Monoclonal antibody. *See* mAb
- Monoexponential model, 102
- Mononuclear cell, 516
- Monosialylganglioside GM1, 42
- Motility-inhibitory effect of
CD82, 73
CD9, 73
- Motility-regulatory protein, 73
- Mouse mammary tumor virus long terminal repeat (MMTV-LTR), 252
- Mouse thymus
expressing immunoglobulin in, 375
expressing Mac-1 in, 375
showing high sialidase activity level, 377
sialidase-positive, 375
- MPR
molecular cloning of, 257
protein identification, 257
- MPR 300
isolation, 258
proteins, homology to, 259
transformation, 258
- MPR 46 DNA
isolation, 258
transformation, 258
- MPR proteins
MPR 300, 257
MPR 46, 257
- mRNA for UDP-galactose transporter, 358
- MRP, 73
- MUC2 carrying GlcNAc 6-sulfation, 356
- Mucin
determination by colometric assay, 84
extraction from tumors, 84
- Mucosa of stomach body, 370
- Mucosal protection and repair, 373
- Multidrug resistance, 583
- Multiglycosyl-transferase complex, 306
- Multiple gene disruption, 389
- Multisialosylated gangliosides, 309
- Multivalent binding, 93
- Murine erythroleukemia (MEL), 559, 564
- Murine lysosomal sialidase gene. *See* Neu-1 gene
- Muscle-Eye-Brain disease. *See* MEB
- Mutagenesis
analysis, 26, 30
on CRE, 344
on GC-box, 344
- Mutant yeast producing mannose-type sugar chain, 385
- Mutation analysis of
CRE, 345
FKRP, 296
GC-box, 344
putative transcriptional elements, 343
- Mutations in
dystrophin gene, 292
glycosylation, 208
- myd
homozygotes, 296
mouse, 296
mutation, 296
- Myelin Basic Protein (MBP), 332
- Myelin oligodendrocyte glycoprotein. *See* MOG
- Myelin-associated glycoprotein. *See* MAG
- Myelin-specific gene regulation, 348
- Myelosuppression recovery, 125
- Myodystrophy. *See* myd
- N
- N-acetylation of deacetylated ganglioside, 18
with [³H] acetic anhydride, 18
with acetic anhydride, 18
- N-acetylation using ganglioside derivative, 18
- N-acetylgalactosamine. *See* GalNAc
- N-acetylglucosamine. *See* GlcNAc
- N-acetylglucosaminyltransferases. *See* GnT
- N-acetylneuraminic acid (α 1-6) galactose.
See Neu5Ac-Gal
- N-acetylneuraminic acid. *See* Neu5Ac
- N-acetylneuraminyl-galactose coupling with human IL-1 α , 119
- N-acylation
deacylated ganglioside derivatives, 18
fluorenyl derivative of 12-aminododecanoic acid activation, 15
fluorenyl derivative of 12-aminododecanoic acid preparation, 14
- N-acylneuraminic acid protein conjugates, 407
- Natural antibodies
heterogeneity, 83
polyspecificity, 83
- Natural ligand binding, 95
- N-cadherin
alkylation, 485
cell-cell adhesion molecule, 484
from melanoma cells, western blot analysis of, 486
glycan moiety, 486
glycans, 483
immunochemical identification of, 483
immunodetection of, 485
immunoprecipitation of, 483, 484
in situ digestion, 485
lectin characterization, 490
oligosaccharides of, 483
protein reduction in, 485
- N-cadherin-specific antibodies, 483
- Neoglycoconjugate, 91, 92, 228
- Neoglycoproteins, advantage of, 119
- Neosynthesis
mechanism, 356
molecular biological background for, 359
- Nerve growth factor. *See* NGF
- Neu-1 gene, 383
- Neu5Ac
chemical modifications of, 407, 410
importance in cancer vaccines, 407
use, 199, 407
- Neu5Ac-Gal
coupling confirmation, 121
detection, 121
- Neu5Ac-Gal-conjugated IL-1 α purification, 120
- Neu5Ac-Gal-IL-1 α , advantage of, 130
- Neu5FPr, immunogenicity of, 413
- Neu5Pr, immunological properties of, 410
- NeuAc(α 1-6)Gal, coupling with rIL-1 α , 120
- Neural cell adhesion molecule (NCAM), 493
- Neuraminidase
digestion with, 368
pre-digestion, 370
pre-treatment on gastric mucosa staining, 371
treatment, 370
- Neuraminidase hydrolyses terminal sialyl residues, 372
- Neuroblastoma cells, 559
- Neuroblastoma cells, ST3GalIII gene in, 498
- Neuroimmune system, 522
- Neurocan, 272
- Neuroglycan C. *See* NGC
- Neuronal membranes, Gangliosides, 302
- Neurotransmission, 128
- Neutral cytosolic, 375
- Neutral pH in immune systems, 375
- Neutral sialidase activity levels, 376
- Neutral sphingomyelinase. *See* nSMase, 41
- Neutrophil glycoprotein, PSGL-1, 91
- NGC
carbohydrate structure of, 273
chondroitin sulfate of, 274
from lysates of brain membrane fraction, 269
HNK-1 epitope on, 275
immunoprecipitation of, 269
immunoreactivity for HNK-1 carbohydrate, 272
lectin blot analysis, 267
lectin reactivity of, 272
ligands, 274
oligosaccharide moieties of, 268
- NGC, carbohydrate moiety of
biochemical characters, 267
immunological characters, 267
- NGC, core protein of
N-linked oligosaccharides, 267
O-linked oligosaccharides, 267
- NGF, 42, 49, 174, 207, 210
- NGF signaling pathway, 210
- N-glycan
in EGF signaling, 209
in growth factor signaling, 207
in NGF-signaling, 210
in Trk, 210
on EGF receptor, 207
synthesis inhibition, 486
- N-glycan structure analysis with
HRP-DSA, 403
HRP-E4-PHA, 403
- N-glycosylated FGF-6, 386
- N-glycosylation
inhibiting tumor cell motility, 72
of factor VIIIc, 183
sites in MPR, 263
sites, 386, 394
- N-hydroxybenzotriazole (BtOH), 410

- Nictaba
 binding, 454
 identification, 453
 lectin, 453
- NIH Image software, 401
- N-linked glycoprotein, 179
- N-linked oligosaccharide
 core oligosaccharide, 386
 of NGC, 274
 outer chain, 386
- N-methyl-D-aspartate (NMDA), 52
- NMR analysis of polysaccharides F1SS, 240
- NMR spectra, 239, 408, 428, 435
- Non-classical plant lectins
 action mode of, 453
 examples of, 452
 in relation with classical, 457
- Non-glycosylated secFGF, comparison with glycosylated, 395
- Non-malignant epithelial cells, 356
- Nonsense-mediated decay (NMD), 499
- Nonulopyranosidonic acid, 408
- Normal cell growth regulation, 158
- Northern blot
 analysis, 59, 152, 295
 MPR proteins, 258
- NP40-solubilized sialidase, 382
- nSMase, 41, 580
- N-terminal amino acid sequence analysis, 392
- Nuclear extracts from
 HOG cells, 342
 LAN-5 cells, 342
- Nuclear levels of proteins
 ATF-1, 345
 CREB-1, 345
 Sp1, 345
 Sp3, 345
- Nuclear magnetic resonance spectroscopy. *See* NMR spectra
- Nuclear protein detection from
 HOG cells, 346
 LAN-5 cells, 346
- Nuclear protein extracts, preparation of, 342
- Nucleosidediphosphate sugars, biosynthesis pathways of, 445
- Nucleotide sequence of
 MNN4 gene, 387
 OCH1 gene, 387
- O
- O-acetylated sialic acid, 199, 552
- O-acetylated sialoglycoconjugates (O-AcSGs), 531
- 1-O-acylceramide
 characterization, 28
 cloning, 28
 dual enzyme activity of, 28
 localization of, 29
 synthase characterization, 28
 synthase pathway, 26
- O
- OD, 92, 410
- O-glycosyl serine linkage, beta elimination of, 372
- O-glycosylation sites of NGC, prediction of, 270
- Oligoglucosides
 butenyl, 430
 butenyl-based, 430
 pentenyl-based, 430
 propenyl, 430
 propenyl-based, 430
- Oligonucleotide sequences, hCGT gene, 341
- Oligosaccharide
 charge analysis of, 475
 in glycoproteins, 207
 in growth factor signaling, 207
 of N-cadherin from human melanoma cell lines, 483
 sequences within glycoprotein glycans, 367
 size analysis of, 475
 stability, elicitor-active, 427
 structure of secFGF, 391
 structures, 209
- Oligosaccharide-hydrolase complexes, 429
- Oligosaccharide-lipid. *See* LLO
- Oligosaccharide-PP-Dol biosynthesis, insulin-enhanced, 182
- O-linked oligosaccharides of NGC, 274
- O-mannosylation, 291
- Open reading frames (ORF), 437
- Optical density. *See* OD
- Oryzata
 composition, 452
 orthologs, 453
 role of, 453
- OSM
 control, 88
 desialylation, 84
- Outer chain addition causing
 immunogenicity in humans, 386
 native glycoprotein activity disappearance, 386
- Ovine submaxillary mucin. *See* OSM
- Oxidant sensitive transcriptional pathway, 334, 337
- Oxidative cell damage, 134
- Oxidative stress, 579
- Oxidative stress in human fibroblast cultures, inducing
 fibroblasts exposed to FeSO₄, 133
 H₂O₂ utilization, 133
 protocol cell treatment, 133
- Oxidized LDL (Ox-LDL), 331
- Oxidized phospholipids, 331, 332
- Oxime
 analogues preparation, 112
 formation procedure, 111
- Ozonolysis, general procedure of, 409
- P
- P. falciparum merozoites, 204
- PAA
 based glycoconjugates, 83, 84
 conjugates, 83, 84
 conjugates purification, 88
- PAF, 336
- 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine. *See* PGPC
- 1-palmitoyl-2-(5-oxo-valeroyl)-sn-glycero-4-phosphocholine. *See* POVPC
- Parasite sialobiology, 199
- PARP, 199
- Pathogenesis in Farber Disease, 43
- pBacHE1/2-GFP construction, 553
- pBacHE1-GFP construction, 553
- PBMC
 9-O-acetylated sialoglycans on, 531
 fluorimetric analysis of, 531, 533
 in VL, 531
 surface sialylation on, 532
 western blot analysis of, 531, 535
- PBS, 267, 268, 342, 376
- PBS wash, 159, 568
- PCR, 291
- PCR approach for hCGT gene, 341
- PDGF, 174, 180
- PDGF receptor, 169
- PDGF receptor suppression, 175
- PDMP
 inhibitory activity for, 25
 isomers for treating
 Colo-205, 157
 SKBR3, 157
- Peanut agglutinin (PNA), 267
- Pepton-induced inflammation, 92
- PE-R, 376
- Peripheral blood leukocytes (PBL), 493
- Peripheral blood mononuclear cells. *See* PBMC
- Peripheral myelin protein-22 (PMP-22), 347
- Perkin-Elmer Model, 429
- Peroxidase activity, 376, 382
- Pertussis toxin (PTX), 218
- PGE2 released from TIG-1 cells, assay for, 121
- PGPC, 331
- pH curves for sialidase of thymus, 378
- Phagocytosis, 203
- Phaseolus vulgaris Erythroagglutinin. *See* E-PHA
- Phenotypes enhancement, transformed, 173
- 1-phenyl-2-decanolamino-3-morpholinopropanol. *See* PDMP
- Phorbol myristate acetate (PMA), 66
- Phosphacan, 267, 272, 274
- Phosphate-buffered saline. *See* PBS
- Phosphatidylserine (PS) distribution, randomized, 322
- Phospholipase A2 family of enzymes, 26
- Phospholipid
 measurement by UDP-galactose, 332
 radioactivity distribution in, 321
- Phosphorylcholine (PC), 537
- Photoactivable ganglioside
 containing nitrophenylazide, 12
 derivative purification, 13
 derivatives synthesis, 11, 14
 for cell culture treatment, 21
- Photolabeling, 11
- Photon emission measurement, 333
- Photozoom invertite microscope, 134
- Phytoerythrin-R. *See* PE-R
- Phylogenetic analysis, 151, 154
- Phytoalexin-elicitor activity, 427
- PIGF, 180

- PIPES buffer, 378
 Pit epithelia (e-PHA), 371
 PKA
 activation, 50
 in neuronal plasticity, 54
 PKA signal
 long-term effects, 54
 on dendritic formation, 54
 short-term effects, 52
 PKA-anchoring for GalNAc signal, 55
 PKC isozymes, 64
 Placental growth factor. *See* PIGF
 Plant lectin
 cellular localization, 451
 classical, 451
 evolutionary relationships of, 450
 histochemistry, 228
 mannose-binding, 529
 mannose-specific, 505
 non-classical, 452
 occurrence, 451
 role of, 449
 structural relationships of, 450
 Plant lectins, classical and non-classical
 evolutionary relationship, 457
 functional relationships, 457
 Plasma glycoprotein
 binding, 537
 CRP binding with, 539
 Plasma membrane
 glycosphingolipids internalization, 311
 internalization, 302
 level, metabolic events at, 309
 recycling, 302
 sialidase, 377
 Plasma membrane glycolipids, 33. *See also* lipid microdomains
 Plasma membrane-associated sialidase, 191, 194
 Plasma membrane-bound
 glycosphingolipids, 309
 sialidase, 309
 Plasmid
 and strains, 108
 DNA, 258
 Plasmid construction for influenza virus, 552
 Plasmodia, causative agents of malaria, 200
 Platelet activating factor. *See* PAF
 Platelet-derived growth factor. *See* PDGF
 PN40 solubilization-buffer, 376
 Pneumococcal C polysaccharide (CPS), 537
 P-nitrophenyl acetate (pNPA), 554
 PO. *See* peroxidase activity
 Polyacrylamide. *See* PAA
 Polyacrylamide gel electrophoresis (PAGE), 537
 Polyacrylic acid carboxyl groups, 93
 Polyclonal antibody, 116, 293, 342, 345
 Polyclonal anti- α Gal antibody isolation, 110
 Polyclonal antibody, anti-ASAL, 529
 Polymerase chain reaction. *See* PCR
 Polysaccharide
 gene clusters, 438
 mannan core, acetolysis of, 240
 Polysaccharide FISS
 cell wall, 239
 chemical analysis of, 240
 from microorganisms, 244
 methylation analysis, 241
 NMR analysis, 240
 partial hydrolysis of, 240
 reductive cleavage of, 241
 Polyspecific lectin, 459
 Polyvinylidene difluoride (PVDF), 267
 POMGnT1
 gene encoding, 295
 mutations, 294
 POMT1, 291, 295
 POVPC-induced A-SMC proliferation, 335
 POVPC-stimulated cell proliferation, 334
 PPMP isomers for treating
 Colo-205, 157
 SKBR3, 157
 Primary antibody, 321
 Proapoptotic
 lipids, 582
 protein functions, 582
 Procyclic acidic repetitive proteins. *See* PARP
 Programmed cell death. *See* apoptosis
 Propidium Iodine, fluorescence staining of, 570
 Protein
 carbohydrate interactions, 449, 452
 concentration determination, 181
 content determination, 121, 122
 determination using Bio-RAD protein assay system, 135
 glycosylation, 182
 quantification, 342
 Protein conjugates of N-acylneuraminic acids
 immunological studies of, 407
 preparation of, 407
 Protein kinase signals in
 neuronal differentiation, 49
 neuronal maturation, 49
 Protein O-Mannosyltransferase 1. *See* POMT1
 Protein-binding ability, 427
 Protein-ganglioside cross-linkage, 12
 Protein-sugar complex, 545
 Proteoglycans purification, 268
 Proteolipid protein (PLP), 348
 Proteolytic cleavage, 59
 Protozoal diseases, sialoglycans in, 199
 Protozoan parasites
 Entamoeba, 199
 Leishmania, 199
 Plasmodia, 199
 Trichomonas, 199
 Trypanosoma, 199
 P-selectin
 binding, 94
 blockers, uncharged, 91
 CRD, 94
 crystal structure of, 92
 inflammation model, 92
 P-selectin glycoprotein ligand (PSGL-1), 91
 PSS-380
 binding measurement, 326
 dye for cancer cells, 326
 fluorescence staining of, 570
 phosphatidylserine detector, 322
 Pullman procedure, 92
 Putative N-linked glycosylation sites, 29
 Putative transcriptional elements, analysis of, 344
 Pyridylamino (PA)-fluorescencelabeled
 biantennary N-glycan. *See*
 GlcNAc2Man3GlcNAc2-PA
 R
 Radiation hybrid mapping, 295
 Radioactive ganglioside
 containing nitrophenylazide, 12
 derivative purification, 13
 derivative, synthesis of, 11, 14
 for treating cell cultures, 21
 Radioactive glycerophospholipids, 310
 Radioactivity distribution in
 glycosphingolipids, 321
 phospholipids, 321
 Radioactivity incorporation by GF/A filtering, 321
 Radiocative precursors for ganglioside, 312
 Radioactive sphingolipids analysis, 568
 Radioimmunoprecipitation assays, 554
 Radiolabeled
 ligand, 429
 protein for tissue distribution, 391
 Radiolabeling of IL-1, 122
 Radioligand binding, 428
 Raft-associated molecules, 215
 Rafts, 63, 64
 Reactive oxygen species. *See* ROS
 Receptor function regulation, 173
 Receptor modulation
 by FACS, 516
 of microglial cells
 CD2, 517
 CD25, 517
 CD4, 517
 MHC class II, 517
 Receptor proteins, 525
 Receptor-like protein tyrosine phosphate.
 See RPTP, 267
 Recombinant
 baculoviruses, 554, 556
 HE1/2-GFP esterases, 556
 HE1-GFP esterases, 556
 vaccinia virus, 554
 viral sialate-O-acetyl esterases, 551
 Reductive amination, 111, 112
 Reductive cleavage analyses, 240
 Replisome complex, 563
 Reverse phase chromatography, 475
 Reverse transcription. *See* RT
 RNA isolation from goat liver tissue, 258
 ROS
 addition, 41
 function in cell death, 41
 generation, 335, 581, 582
 RPTP, 267
 RT, 291
 RT-PCR
 for galectin fingerprinting, 228
 for galectin in tumor cells, 228
 for GNT control, 153
 for MPR proteins, 257, 258
 for ST3GalIII gene, 494
 monitoring, 227

- S
- SA. *See* sialic acid
- SAA, 122
- Saccharides, structural information about, 367
- Saccharide-signaling pathways, 50
neural functions maintenance, 50
neuronal development, 50
- Saccharomyces cerevisiae, 385, 386
- Salmonella hisG gene for gene disruption, 389
- Salvage pathways for gangliosides, 309
- Sambucus nigra agglutinin. *See* SNA
- SAP, 308
- Saposines. *See* SAP
- Scanning confocal microscopy, 67
- Scanning electron microscopy. *See* SEM
- SDAV HE gene
cloning, 554
expression, 554
- SDS-PAGE
analysis, 120, 181, 267, 270, 388, 527, 532
electrophoresis, 483
for CRP purification, 538
use, 525, 527
- SDS-polyacrylamide gel electrophoresis. *See* SDS-PAGE
- SDS-resistant gangliosideprotein, high affinity, 66
- SecFGF
blood clearance of, 391
by mutant yeast, 386
distribution to tissues
bone, 392
brain, 392
intestine, 392
kidney, 392
liver, 392
lung, 392
spleen, 392
stomach, 392
HUVEC proliferation activities of, 392
iodination, 389
oligosaccharide structure of, 391
properties of, 390
purification of, 388
- SecFGF production with Man5GlcNAc2-type oligosaccharide, 391
- SecFGF, types of
M5-FGF, 395
M8-FGF, 395
Wild-FGF, 395
- SecFGFs, sugar chain structures of
complex-type, 386
high-mannose type, 386
mannan-type, 386
- β -secretase for Alzheimer's disease pathogenesis, 59
- β -secretase, roles of, 59
- Seed lectins, 451
- Selectin
assay, 92
ligands in cancer cells, 361
- Self-quenching process, 21
- SEM
for E-rosette-forming microglia, 516
study, 517, 520
- Sequencing of ST3GalIII gene, 494
- Sera
binding activity for, 85
specificity, 84
with high IgG-binding activity, 85
- Serine palmitoyltransferase (SPT), 39
- Serum amyloid A. *See* SAA
- Serum diagnosis of cancers, 355
- Serum levels measurement in
glucose, 122
NOx levels, 122
- SAA, 122
- Serum NOx level, 124
- Sheep red blood cells (SRBC), 516
- SiaLex. *See* sialyl Lewis X
- Sialic acid
9-O-acetylated, 531
acquisition in parasitic protozoa, 200
at N-linked glycosylation, 74
binding lectins, 200
De-novo synthesis of, 202
esterification of, 485
for human erythrocytes invasion, 204
from cell surfaces, 375
in immune systems, 375
in malignant cells, 189
loading of glycoconjugates, 409
loading, 409, 411
- Sialic acid adsorption in
Leishmania donovani, 202
Toxoplasma gondii, 202
- Sialic acid, importance of
ligand for selectins, 119
sialoglycoproteins clearance prevention, 119
- Sialidase
and malignancy, 189
at neutral pH in immune systems, 375
encoding, 191
endogenous membrane bound, 375
expression alteration, 192
expression in cancer, 192
in mammalian cells, 189
in nucleoplasm, 190
staining, 376
subcellular localization of, 191
treatment, 375
- Sialidase activity
in PIPES buffer, 378
NP40-solubilized, 382
using soluble fraction, 377
- Sialidase activity assayed at
acidic pH, 378
pH 4.5, 377
pH 7.0, 377
pH 7.0, 377
pH 7.0, 382
- Sialidase activity in murine thymus
lysosomal membrane-type, 379
plasma membrane-type, 379
soluble enzyme, 379
- Sialidase activity in organs
bone marrow, 378
heart, 378
kidney, 378
liver, 378
lung, 378
- lymph node, 378
rat thymus, 378
spleen, 378
thymus, 378
- Sialidase activity, types of
crude-membrane fractions, 377
peripheral lymph nodes, 377
spleen, 377
thymus, 377
- Sialidase, types of
cytosolic, 190
intralysosomal, 190
plasma membrane, 190
- Sialidase-positive cells
histochemical active staining of, 380
histochemical analysis of, 376
histochemical staining of, 375
localization determination, 381
localization of, 375
microbial, 192
origin, 189
with high peroxidase activity levels, 382
- Sialodacryoadenitis virus (SDAV), 551
- Sialoglycans in protozoal diseases
biological roles, 199
detection, 199
modes of acquisition, 199
- Sialoglycans on parasitic protozoa, 199
- Sialoglycoconjugates in parasitic protozoa, 203
- Sialoglycoproteins, 119
- Sialyl Lewis A
cancer-associated induction of, 353
determinant in cancer cell, 357
enhancement, 355, 358
expression neosynthesis, 359
in colon cancer cells, 353
in non-malignant colonic epithelium, 353
synthesis, 356
- Sialyl Lewis X
cancer-associated induction of, 353
enhancement, 358
expression neosynthesis, 359
in colon cancer cells, 353
in non-malignant colonic epithelium, 353
synthesis, 356
- Sialylated
GlcNAc determinants, 356
glycotopes, 200
precursors, 357
- Sialylation
in cancer cells, 189
of cancers, 355
- Sialyl-Lex epitope in metastatic potential, 71
- α 2,3-Sialyltransferases, 357
- α 2,6-sialyltransferase. *See* ST6Gal I
- Sialyltransferase enzymatic activities, 358
- 2,3-sialyltransferase III identification. *See* ST3Gal III
- Sialyltransferase isoenzymes
ST3Gal-II, 358
ST-3O, 358
- SiaTn
binding, 87
glycotopes, 83
- SiaTn-positive, 87

- Siglecs
 CD22, 119
 MAG, 119
 sialoadhesion, 119
- Siglecs presence in
 B lymphocytes, 119
 macrophage subsets, 119
 oligodendrocytes, 119
- Signal transducer molecules, 64
- Signal transduction
 by ceramide, 567
 concept, 449, 454
 in human PBL, 66
 processes, 33
 regulation in T lymphocytes, 63
- Signal transduction cascades, 55
- Signaling function modulation, 64
- Signaling pathways, ceramide metabolism and, 25
- Silica gel column chromatography, 14, 408
- Size exclusion chromatography, 108, 250, 463
- SKBR3 cells
 apoptosis of, 157, 319
 culture, 463, 568
 morphology, 465
 proliferation, 465
- SKBR3 treatment with
 GD1b, 319
 GD3, 319
 PDMP isomers, 157
 PPMP isomers, 157
 with betulinic acid, 563
 with GD3 ganglioside, 563
 with L-PDMP, 563
 with L-PPMP, 563
 with Melphalan, 563
 with Tamoxifen, 563
- S-layer glycan biosynthesis
 involving nucleosidediphosphate sugars, 445
 loci of Bacillaceae, 435
- S-layer glycan composition, 436
- S-layer glycoproteins, 435. *See also*
 glycoconjugates, cell surface
- S-layer glycosylation. *See* slg
- S-layer precursor protein, 437
- S-layer protein glycosylation, comparison of, 445
- SLex
 at focal de-differentiation site, 72
 staining, 72
- slg
 for nanobiotechnology, 436
 gene clusters
 glycan processing genes, 438
 glycosyltransferase genes, 438
 of *Aneurinibacillus thermoaerophilus*, 441
 of Bacillaceae, 438
 of *Geobacillus stearothermophilus*, 442
 of *Thermoanaerobacterium
 thermosaccharolyticum*, 443
 operon, 438
- SM3
 abrogating phenotypes, 172
 integrin expression regulation, 170
 tumorigenesis regulation, 170
 cell adhesion suppression, 170
 gene expression of integrin molecules
 suppression, 170
- SM3-reconstituted cells, 170, 173
- Sn-2 ester bond of phospholipids, 26
- SNA-specific binding, 542
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *See* SDS-PAGE
- Sodium-acetate buffer, 379
- Solid-phase immobilized antigen, 110
- Spectrofluorometry, use of, 376
- Sphingoid bioregulators, 302
- Sphingolipid
 biochemistry, 25
 biosynthesis, 322
 ceramide N-deacylases, 308
 ceramide, 26
 ceramide-1-phosphate, 26
 multiple glycosphingolipids, 26
 sphingosine, 26
 sphingosine-1-phosphate, 26
- Sphingolipid activator proteins. *See* SAP
- Sphingolipid-enriched membrane, 13
- Sphingomyelin (SphM) hydrolysis, 159
- Sphingomyelin synthesis, 40
- Splicing pattern of ST3Gal III, 498
- Statistical probit analysis, 526
- ST3Gal III
 in neuroblastoma cells, 498
 isotranscripts from human foetal brain, 493
 isotranscripts in adult brain, 499
- ST3GalIII gene
 amino acid sequences, 494
 cloning of, 494
 sequencing of, 494
 splicing pattern of, 498
- ST6Gal I
 cleavage by BACE1, 59
 function of, 59
 mutant, 60
 use, 59
- Streptomyces hyalurolyticus, 465
- Sucrose-density gradient ultracentrifugation, 34
- Sugar
 extraction, 485
 microcolumn clean-up of, 485
 nucleotides, 185, 435
 removal from gangliosides, 307
- Sugar-binding triad, 549
- Sugar chain
 on FGF functions, 386
 synthesis, 476
- Sugar chain analysis
 of mannoproteins, 395
 using secFGF fraction, 388
- Sugar chain branch structures, 388. *See also*
 secfgf, sugar chain structures of
- Sugar chain structure
 of hCG, 473
 on tissue distribution, 391
- Sugar transporters, gene expression of, 353
- Sulfatide SM3, 169
- Sulfatide, 33
- Superoxide
 measurement in intact cells, 333
 radical generation, 138, 334
- Superoxide dismutase (SOD), 133, 135
- Suppressed-cAMP-inducible protein (SCIP), 347
- Surface epithelial cells, lectin DBA-stained, 372
- Surface ligand interactions, 34
- Surface mucosal epithelium, staining with DBA, 372
- Surface parietal cells, lectin DBA-stained, 372
- Surface sialylation on PBMC, 532
- Substrate specificity assay, 112
- Svennerholm method, 409
- Systemic Lupus (SLE), 537
- T
- T cell
 activation, 63, 522
 apoptosis, GEM in, 66
 sialidase activity, 382, 383
- T cell factor-1. *See* TCF-1
- T cruzi gene transfection, 203
- T lymphocytes, 63, 64
- T11TS
 glycoprotein, 515
 immunomodulatory property of, 518
 Ligand-receptor interaction, 520
- T11TS/SLFA-3, glycopeptide, 516
- TACA, 407
- Tamoxifen (TMF), anti-cancer drugs, 563, 564
- TBS, 83, 399, 401
- TCF-1, 339
- TCR-initiated signaling, 66
- Terminal β -galactose, 372
- Terminal α -L-fucosyl residues, 371
- Terminal N-acetylnneuraminic acid expression, 371
- Tetramethylsilane. *See* TMS
- Tetraspanin. *See* Tsp
- TF glycotopes, 83
- Therapeutic glycoproteins, 385
- Thin layer chromatography. *See* TLC
- Thymus macrophages, 383
- Time-of-Flight-mass spectrometry. *See* TOF-MS
- TIRF spectroscopy, 214
- Tissue distribution
 analysis using secFGF fraction, 388
 in mammalian cells, 385
 of fibroblast growth factor, 385
 of IL-1 α , 126
 of M5-FGF, 392
 of M8-FGFs, 392
- Tissue homogenization, 376
- Tissue targeting therapy, 385, 386, 396
- TLC, 11, 108, 193, 408
- TMS, 408
- Tn glycotopes, 83
- Tn-binding activity, 86
- TNF, pathogenic role for, 583
- TNF-induced
 fibroblast apoptosis, 580
 lethality, 580
 lipopolysaccharide, 580
- TNM stage, 400
- TOF-MS, 121, 124
- Toluene scintillation system, 160, 163, 568
- Total internal reflection fluorescence spectroscopy. *See* TIRF spectroscopy

- Toxoplasma gondii, causative agent of
 Toxoplasmosis, 200
 Toxoplasma gondii, sialic acid adsorption in, 202
 Tracer-to-tracee molar ratio. *See* TTR
 Transacylase purification, 30
 Transfucosylation, 357
 Trans-glycosylation in Trypanosoma, 200
 Transient transfection assay, 341
 Transit cells, 373. *See also* cells, in neck region
 Transmembrane sphingolipid, ceramide, 158
 Trans-sialidases, 199, 203
 Trefoil peptides, 373
 Trichloroacetic acid (TCA), 516
 Trifluoropropionyl group, 410
 Triple disruptant mutant construction, 389
 Triple disruptant strain, 387
 Tris buffered saline. *See* TBS
 Trk
 activation regulation, 210
 for intercellular localization, 210 N-glycan in,
 210
 signaling, 210
 Trypan Blue staining method for breast cancer
 cells, 321
 Trypanosoma brucei-italics
 ngana in domestic animals, 200
 sleeping sickness in humans, 200
 Trypanosoma cruzi-italics, 199
 Trypsin treatment, 21
 Tsp, 73
 Tsp-dependent cellular functions, 73
 TTR, 99, 101
 TTRKIV, 102
 Tubular cell-specific regulation, 151
 Tumor
 diagnosis, 227
 galectinology, 227
 histopathology, 228
 marker, 227
 metastasis, 179
 progression, 179
 Tumor cell
 galectins, 228
 motility, 75
 Tumor cell motility inhibition
 apoptosis promotion, 72
 integrin/tetraspanin complex, 72
 Tumor malignancy control by
 angiogenesis in tumor cells, 71
 apoptotic susceptibility, 71
 invasiveness of tumor cells, 71
 matrix-destroying protease activity, 71
 motility of tumor cells, 71
 tumor cell adhesion, 71
 Tumor-associated antigens
 SiaTn, 83
 TF, 83
 Tn, 83
 Tumor-associated carbohydrate antigens. *See*
 TACA
 Tumorigenesis regulation, 170
 Tumor-node-metastasis stage of cancer. *See* TNM
 stage
 Tyrosine kinase receptors, 65
 Tyrosine kinases in HIV entry, 218
 U
 UDP, 399
 UDP-donor utilization, 111
 UDP-Gal conversion, 107
 UDP-galactose
 measurement, 332
 transcriptional regulation of, human 339
 UDP-galactose 4-epimerase (GALE), 359
 UDP-galactose transporter gene (UDP-GalT1),
 358
 UDP-galactose, 339. *See also* CGT
 UDP-GlcNAc, 199
 Ultracentrifugation, sucrose-density gradient, 34
 Ultrafiltration membrane, 475
 Ultrasonography for WWS diagnosis, 295
 Untranslated. *See* UTR
 Up-regulation of
 HYAL 1, 469
 HYAL 2, 469
 5'-upstream sequence of GNT gene, 153
 Uridine diphosphate N-acetylglucosamine. *See*
 UDP-GlcNAc
 Uridine diphosphate. *See* UDP UTR, 493
 UV spectrometer, 389
 V
 Vaccinia virus (VV), 552, 554
 [^{13}C]valine enrichment determination, 101
 [^{13}C]valine-labelling, 99
 Van der Waals interactions, 548
 Varian Unity spectrometer, 110
 Vascular endothelial growth factor, 180
 Vasculogenesis, 179
 Verotoxin, 33, 34
 Vimentin IF, 312
 Viral O-acetyltransferases
 in coronaviruses, 551
 in influenza C viruses, 551
 Viral sialate-O-acetyltransferases, recombinant, 551
 Visceral Leishmaniasis (VL), 204, 531, 537
 Visceral Leishmaniasis (VL) patients
 membrane fractions from, 533
 PBMC of, 532
 Voltage-dependent anion channel (VDAC), 41
 W
 Walker-Warburg syndrome. *See* WWS
 Warburg effect, 353, 359
 WBC, 125
 WBC recovery, 126, 129, 130
 Western blot
 detection system, 343
 for caspases activation identification, 160
 for radioactivity identification, 321
 Western blot analysis
 for caspases identification, 570
 of bile glycoproteins, 403
 of bile proteins, 401, 405
 of Caspase-3, 574
 of caspase-3 activation, 322
 of NGC, 270
 of PBMC, 531, 535
 of secFGF, 390
 Western blotting
 for KM +, 505
 N-cadherin, 485
 of parasite membranes, 202
 system, 151, 388, 390
 Wheat germ agglutinin (WGA), 267
 White blood cell. *See* WBC
 WWS
 abnormalities in
 cerebellar malformation, 294
 congenital macrocephaly, 294
 retinal malformation, 294
 autosomal recessive CMD, 294
 X
 Xenopus laevis, pentraxin of, 546
 Xenotransplantation, 107, 112
 X-NANA, 375
 X-NANA for sialidase positive cell detection, 382
 X-ray crystallographic analysis, 126, 191, 546,
 548
 Y
 Yeast-specific glycosylation system, 386